Lipid profile during rhGH therapy in pediatric renal transplant patients

Pediatric Transplantation

Volumn 6, Issue 2, 2002, Pages 127-131

  Ghio, L ^a   Damiani, B ^a   Garavaglia, R ^a   Oppizzi, G ^b   Taioli, E ^c   Edefonti, A ^a  

^a Az Ospedaliera ICP   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Lipoprotein (a); Recombinant human growth hormone; Renal transplant

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN A; LIPID; LIPOPROTEIN A; RECOMBINANT GROWTH HORMONE; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HYPERLIPOPROTEINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MORBIDITY; PATIENT MONITORING; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANALYSIS OF VARIANCE; CHILD; FEMALE; GRAFT REJECTION; GROWTH DISORDERS; GROWTH HORMONE; HUMANS; KIDNEY TRANSPLANTATION; LIPOPROTEIN(A); MALE; MONITORING, PHYSIOLOGIC; PROBABILITY; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 0036246939     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2002.01054.x     Document Type: Article

References (53)

1. Sequential analysis of the lipid profile of children post-renal transplantation
2. Persistent hyperlipidemia in renal transplant patients
3. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients
4. Prevalence of hyperlipidemia in renal transplant recipients: Association with immunosuppressive and antihypertensive therapy
5. Risk factors for accelerated atherosclerosis in renal transplant recipients
6. Lipid abnormalities in uremia, dialysis and transplantation
7. Effects of chronic uremia, hemodialysis and renal transplantation on plasma lipids and lipoproteins in man
8. Hyperlipidemia in children. The role of uremia, steroids and cyclosporine therapy
9. Risk factors for hyperlipidemia in long-term pediatric renal transplant recipients
10. The mysteries of lipoprotein(a)
11. Lipoprotein(a) thrombotic and atherogenic
12. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients
13. Lipoprotein(a): Heterogeneity and biological relevance
14. Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis
15. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface
16. Defensin promotes the binding of lipoprotein(a) to vascular matrix
17. Apo(a) pheno-types and Lp(a) concentrations in renal transplant patients
18. Lipoprotein(a) plasma concentrations after renal transplantation: A prospective evaluation after 4 years of follow-up
19. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis
20. Increased lipoprotein(a) concentrations in chronic renal failure
21. Metabolic effects of long term growth hormone treatment in prepubertal children with chronic renal failure and after kidney transplantation
22. Effects of growth hormone in short children after renal transplantation
23. A longitudinal study of the natural history of growth post-transplantation
24. Randomised controlled trial of recombinant growth hormone in prepubertal and pubertal renal transplant recipients
25. Treatment of peripubertal children after renal transplantation (RTx) with recombinant human growth hormone, auxological data and effects on insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) during 24 months
26. Factors affecting growth and strategies for treatment in children after renal transplantation
27. Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone
28. Long-term use of recombinant human growth hormone in children with chronic renal insufficiency
29. Impact of growth hormone treatment on a Belgian population of short children with renal allografts
30. Growth hormone treatment in growth-retarded adolescents after renal transplant
31. Short- and long-term effects of growth hormone treatment on lipid, lipoprotein, and apolipoprotein levels in short normal children
32. Beneficial effect of growth hormone on atherogenic risk in children with growth hormone deficiency
33. Treatment with growth hormone increases lipoprotein(a) serum levels in children with chronic renal insufficiency
34. Increase of serum lipoprotein(a) levels during growth hormone therapy in normal short children
35. Apolipo-protein(a) gene accounts for greath than 90% of the variation in plasma lipoprotein(a) concentrations
36. Variation in lipoprotein(a) concentrations individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production
37. Growth hormone and hepatic lipoprotein metabolism
38. Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: Gender-specific metabolic effects
39. Effect of short-term treatment with recombinant human growth hormone on lipids and lipoproteins in women and men without growth hormone disturbances
40. Low dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low density lipoprotein cholesterol concentrations in middle-aged men
41. An open 36-month study of lipid changes with growth hormone in adults: Lipid changes following replacement of growth in adult acquired growth hormone deficiency
42. The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone-deficient adults
43. Different effects of continuous and intermittent patterns of growth hormone administration on lipoprotein levels in growth hormone-deficient patients
44. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents
45. The delayed effect of growth hormone on renal function in humans
46. Acute renal graft rejection after treatment with human growth hormone
47. Bone disease in patients receiving growth hormone
48. Growth hormone, insulin-like growth factor-I, and benign intracranial hypertension
49. Serum cholesterol, blood pressure and mortality: Implications from a cohort of 361,662 men
50. Lipoproteins, cardiovascular disease, death
51. Lipid abnormalities in renal disease
52. Serum lipoprotein(a) in renal transplant recipients receiving cyclosporin monotherapy
53. Lipoprotein(a) and accelerated coronary arterial disease in cardiac transplant recipients